HLA-A and neoplasm: While the immunogenicity of the short peptide vaccine H3.3K27M26-35 is restricted to HLA-A*02+ patients17, we provide evidence of presentation of H3K27M neoepitope on MHC class II on tumor cells and on APCs across multiple HLA types (Fig. 4).